STOCKHOLM, Sweden, 9 June 2025 Avia Pharma is expanding its self-care portfolio with the launch of Oralmedic, a fast and effective treatment for mouth ulcers, across the Nordic region. – We are proud to bring Oralmedic back to the Nordic markets. It has been highly requested by both consumers and

STOCKHOLM, Sweden, 1 January 2025 Avia Pharma is announcing its official representation in the Nordics of Theramex, a global specialty pharmaceutical company that specializes in women’s health products.   Based in London, Theramex is a global pharmaceutical company dedicated to Women’s Health in over eighty countries, across five continents. The

STOCKHOLM, Sweden, 2 February 2024 – Avia Pharma Holding AB (“Avia” or the “Company”) has completed the acquisition of Neubourg Skin Care GmbH (“Neubourg”), a leading German dermatology company, specialized in skin, foot and nail care. Through the acquisition, Avia adds a strong dermatology brand portfolio in Germany to its platform,

STOCKHOLM, Sweden, 2 February 2024 – During January, Avia Pharma Holding AB (“Avia” or the “Company”), welcomed Impilo AB as a new owner and partner to the co-founders. Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies. The partnership with Impilo will allow Avia to execute

Avia Pharma has today completed the acquisition of ACO Vitamin D water and will as the new marketing authorisation holder re-launch the pharmaceutical in the Swedish market in Q4 this year. “The acquisition allows us to continue offering this complement to D-vitamin oil”, says Marie Wikman, Business Unit Director Avia

Avia Pharma is launching Nyvigan in Swedish pharmacies. Nyvigan (nystatin) is a combination treatment (pessaries + cream) for the treatment of vulvovaginal Candida. Vulvovaginal candidiasis is an infection of the estrogenised vagina and vestibulum which can also extend to the outer sides of the labia minora, the labia majora, the

Avia Pharma has today completed the acquisition of Unimedic’s Vitamin D oil. “The acquisition is in line with Avia Pharma’s strategy to own more products and will complement our existing portfolio”, says Jacob Calmvik, CEO of Avia Pharma. For further information, please contact Jacob Calmvik, CEO Avia Pharma, jacob.calmvik@aviapharma.se, +46 703

Avia Pharma has today completed the acquisition of Allergika Pharma GmbH. The company has a turnover of close to 15 million EUR and is placed in Wolfratshausen, near Munich. Allergika is a German pharmaceutical company focused on the allergy market. It sells both dermatology products and encasing under its own

Avia Pharma has today completed the acquisition of Decem Pharma. Decem Pharma is a Finish pharmaceutical company with its own brands with strong market positions, such as Magnecit and Otocur. The acquisition of Decem Pharma is Avia Pharma’s first acquisition outside of Sweden and part of its strategy to build

Following a strong sales increase in the current portfolio, Avia Pharma and Perrigo have deepened the relationship to also include Vectavir®, Vectatone®, Oralmedic® and Predictor®.

Avia Pharma appoints Mattias Wik as Business Unit Director Oncology/Urology.